

1 **Altered gene expression and PTSD symptom dimensions in World Trade Center responders**

2

3 Shelby Marchese<sup>1</sup>, Leo Cancelmo<sup>2</sup>, Olivia Diab<sup>2</sup>, Leah Cahn<sup>2</sup>, Cindy Aaronson<sup>2</sup>, Nikolaos P.  
4 Daskalakis<sup>2,3</sup>, Jamie Schaffer<sup>2</sup>, Sarah R Horn<sup>2</sup>, Jessica S. Johnson<sup>1</sup>, Clyde Schechter<sup>4</sup>, Frank Desarnaud<sup>2,5</sup>,  
5 Linda M Bierer<sup>2,5</sup>, Iouri Makotkine<sup>2,5</sup>, Janine D Flory<sup>2,5</sup>, Michael Crane<sup>6</sup>, Jacqueline M. Moline<sup>7</sup>, Iris  
6 G. Udasin<sup>8</sup>, Denise J. Harrison<sup>9</sup>, Panos Roussos<sup>1,2,10-12</sup>, Dennis S. Charney<sup>2,13,14</sup>, Karestan C Koenen<sup>15-</sup>  
7 <sup>17</sup>, Steven M. Southwick<sup>18-19</sup>, Rachel Yehuda<sup>2,5</sup>, Robert H. Pietrzak<sup>18-19</sup>, Laura M. Huckins<sup>1,2,10-</sup>  
8 <sup>12,20\*</sup>, Adriana Feder<sup>2\*</sup> (\* equal contribution)

9

10 <sup>1</sup> Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York,  
11 NY 10029, USA

12 <sup>2</sup> Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

13 <sup>3</sup> Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA

14 <sup>4</sup> Department of Family and Social Medicine, Albert Einstein College of Medicine of Yeshiva  
15 University, Bronx, NY, USA

16 <sup>5</sup> Department of Psychiatry, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA

17 <sup>6</sup> Department of Environmental Medicine and Public Health, Icahn School of Medicine at Mount Sinai,  
18 New York, NY, USA

19 <sup>7</sup> Department of Occupational Medicine, Epidemiology and Prevention, Zucker School of Medicine at  
20 Hofstra/Northwell, Great Neck, NY, USA

21 <sup>8</sup> Environmental and Occupational Health Sciences Institute, School of Public Health, Rutgers  
22 University, Piscataway, NJ, USA

23 <sup>9</sup> Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, NYU School of  
24 Medicine, New York, NY, USA

25 <sup>10</sup> Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York,  
26 NY 10029, USA

- 27 <sup>11</sup> Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New  
28 York, NY 10029, USA
- 29 <sup>12</sup> Mental Illness Research, Education and Clinical Centers, James J. Peters Department of Veterans  
30 Affairs Medical Center, Bronx, NY 14068, USA
- 31 <sup>13</sup> Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- 32 <sup>14</sup> Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New  
33 York, USA.
- 34 <sup>15</sup> Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston,  
35 MA, USA.
- 36 <sup>16</sup> Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA, USA.
- 37 <sup>17</sup> Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA.
- 38 <sup>18</sup> Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
- 39 <sup>19</sup> Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, VA Connecticut  
40 Healthcare System, West Haven, CT, USA
- 41 <sup>20</sup> Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New  
42 York, NY 10029, USA
- 43
- 44
- 45
- 46

47 **Abstract**

48  
49 Despite experiencing a significant trauma, only a subset of World Trade Center (WTC) rescue  
50 and recovery workers developed posttraumatic stress disorder (PTSD). Identification of  
51 biomarkers is critical to the development of targeted interventions for treating disaster responders  
52 and potentially preventing the development of PTSD in this population. Analysis of gene  
53 expression from these individuals can help in identifying biomarkers of PTSD.

54  
55 We established a well-phenotyped sample of 371 WTC responders, recruited from a longitudinal  
56 WTC responder cohort, by obtaining blood, self-reported and clinical interview data. Using bulk  
57 RNA-sequencing from whole blood, we examined the association between gene expression and  
58 WTC-related PTSD symptom severity on (i) highest lifetime Clinician-Administered PTSD  
59 Scale (CAPS) score, (ii) past-month CAPS score, and (iii) PTSD symptom dimensions using a 5-  
60 factor model of re-experiencing, avoidance, emotional numbing, dysphoric arousal and anxious  
61 arousal symptoms. We corrected for sex, age, genotype-derived principal components and  
62 surrogate variables. Finally, we performed a meta-analysis with existing PTSD studies (total  
63 N=1,016), using case/control status as the predictor and correcting for these variables.

64  
65 We identified 66 genes significantly associated with highest lifetime CAPS score (FDR-  
66 corrected  $p < 0.05$ ), and 31 genes associated with past-month CAPS. Our more granular analyses  
67 of PTSD symptom dimensions identified additional genes that did not reach statistical  
68 significance in our overall analysis. In particular, we identified 82 genes significantly associated  
69 with lifetime anxious arousal symptoms. Several genes significantly associated with multiple  
70 PTSD symptom dimensions and lifetime CAPS score (*SERPINA1*, *RPS6KA1*, and *STAT3*) have

71 been previously associated with PTSD. Geneset enrichment of these findings has identified  
72 pathways significant in metabolism, immune signaling, other psychiatric disorders, neurological  
73 signaling, and cellular structure. Our meta-analysis revealed 10 genes that reached genome-wide  
74 significance, all of which were down-regulated in cases compared to controls (*CIRBP*, *TMSB10*,  
75 *FCGRT*, *CLIC1*, *RPS6KB2*, *HNRNPUL1*, *ALDOA*, *NACA*, *ZNF429* and *COPE*). Additionally,  
76 cellular deconvolution highlighted an enrichment in CD4 T cells and eosinophils in responders  
77 with PTSD compared to controls.

78  
79 The distinction in significant genes between lifetime CAPS score and the anxious arousal  
80 symptom dimension of PTSD highlights a potential biological difference in the mechanism  
81 underlying the heterogeneity of the PTSD phenotype. Future studies should be clear about  
82 methods used to analyze PTSD status, as phenotypes based on PTSD symptom dimensions may  
83 yield different gene sets than combined CAPS score analysis. Potential biomarkers implicated  
84 from our meta-analysis may help improve therapeutic target development for PTSD.

## 85 **Introduction**

86 Posttraumatic stress disorder (PTSD) is a complex psychiatric disorder that can develop after  
87 experiencing a traumatic event. The attacks on the World Trade Center (WTC) on September 11,  
88 2001 and their aftermath had a substantial impact on the physical and mental health of WTC  
89 rescue, recovery and clean-up workers, but only a subset developed PTSD. These differing  
90 clinical outcomes after experiencing trauma imply a role for biological and genetic influence in  
91 PTSD. Our cohort provides an unprecedented opportunity into PTSD insights, because they have  
92 been deeply phenotyped for a shared, specific trauma.

93  
94 Understanding the biological mechanisms underlying PTSD will require careful dissection and  
95 analysis of many constituent symptoms and risk factors. PTSD is uniquely heterogeneous among  
96 psychiatric disorders, with complex and detailed diagnostic criteria that allow for 636,120  
97 different combinations of symptoms<sup>1</sup>, and 79,794 different symptom combinations. Additional  
98 heterogeneity in PTSD stems from the type and extent of trauma. It has been well established  
99 that PTSD is a heterogenous disorder and that trauma type plays a role in differential outcomes.  
100 In the field of WTC exposures, some work has already been done to elucidate gene expression  
101 and clinical outcomes.<sup>2-10</sup> Further, work by our group and others has demonstrated differential  
102 genetic heritability of PTSD according to trauma-type<sup>11,12</sup>.

103  
104 Identification of biomarkers will be critical to the development of targeted interventions for  
105 treating disaster responders and potentially preventing the development of PTSD in this  
106 population. Gene expression analysis from WTC responders is uniquely useful to deduce the  
107 biological heterogeneity in PTSD, given their exposure to a similar and well-documented trauma.

108 Data on WTC-related traumatic exposures of responders analyzed here, in combination with  
109 their heterogenic clinical outcomes, makes this a critical study to understand PTSD development  
110 and chronicity after shared traumatic events. Although candidate gene expression and  
111 methylation studies have explored genes involved in canonical stress signaling pathways in  
112 PTSD, regulated by the hypothalamus-pituitary-adrenal (HPA) axis, and immune and  
113 sympathetic nervous systems, few have been able to control for length of time since exposure,  
114 nor so specifically delineate trauma type and secondary exposures such as dust cloud severity.  
115 While the WTC-related exposures experienced by rescue, recovery and clean-up workers in this  
116 cohort ranged in severity, the traumatic event –encompassing the 9/11 attacks and their  
117 aftermath– happened in a discrete, specific time window. Further, this sample is highly  
118 phenotyped with in-person clinical psychiatric evaluations, also including medical examination  
119 and laboratory testing.

120

121 The existence of this cohort and the generous participation of many responders to the WTC  
122 disaster enabled us to generate a large gene expression data set of 355 donors, to our knowledge  
123 the largest single traumatic event expression data set to date. We used the Clinician-  
124 Administered PTSD Scale (CAPS)<sup>13</sup> score as a quantitative measure of PTSD symptom severity  
125 rather than a case/control definition, thus substantially increasing statistical power in this  
126 study.<sup>14-16</sup> To our knowledge, ours is the first gene expression study to incorporate total CAPS  
127 scores and PTSD symptom dimensions as outcomes.

128

129 **Methods**

130 **Participants**

131 The WTC Health Program (WTC-HP) is a regional consortium of five clinical centers  
132 established in the greater New York City area by the Centers of Disease Control and Prevention  
133 in 2002, with the goal of providing health monitoring and treatment to WTC responders,  
134 comprising the WTC-HP General Responder Cohort<sup>17</sup>. We recruited participants from the WTC-  
135 HP Responder Cohort who had completed at least three periodic health monitoring visits at one  
136 of the four WTC-HP clinical centers participating in this study – Mount Sinai Medical Center,  
137 New York University, Northwell Health, and Rutgers/The State University of New Jersey – and  
138 who had provided signed consent to be contacted for research studies. Stratified random  
139 sampling was employed to ensure selection of WTC responders spanning the full range of WTC-  
140 related PTSD symptom severity, from no/minimal symptoms to severe/chronic PTSD symptom  
141 levels on the PTSD Checklist – Specific Version (PCL-S)<sup>18</sup> completed during periodic health  
142 monitoring visits to the WTC-HP. Individuals with a lifetime history of chronic psychotic  
143 disorder or bipolar disorder type I, substance abuse/dependence or alcohol dependence over the  
144 prior three months, current pregnancy, acute medical illness or exacerbation of chronic medical  
145 illness, history of significant head injury or cerebrovascular accident, changes in medications or  
146 medication dosages over the prior month, or who were taking oral or regularly injected steroid  
147 medications were excluded from the study.

148

149 The study, conducted between April 2013 and September 2017, was approved by the  
150 Institutional Review Board of the Icahn School of Medicine at Mount Sinai, and all participants  
151 provided written informed consent. A total of 471 WTC responders completed in-person clinical

152 assessments, yielding a final sample of 371 participants who met study eligibility criteria and  
153 completed study procedures, and 355 of those who had viable RNA-sequencing data (Figure 1).  
154 The mean age of participants was 54.1 (SD=8.3) years, 82% were male; ethnicity proportions are  
155 given in **Table 1**. The sample was composed of 40.8% police responders and 59.2% non-  
156 traditional responders (e.g., construction workers).

157

### 158 **Assessments**

159 Data on 10 WTC-related exposures<sup>19</sup>(e.g., exposed to human remains, received treatment for an  
160 illness/injury during WTC recovery work) was obtained from interviews and self-report  
161 questionnaires completed by participants during their first health-monitoring visit to the WTC-  
162 HP, an average of 4.3 (SD=2.7) years following 9/11/2001. In-person clinical assessments were  
163 conducted an average of 13 (SD=2.3) years following 9/11/2011. Trained Masters- or PhD-level  
164 clinical interviewers administered the Structured Clinical Interview for DSM-IV (SCID)<sup>1</sup> to  
165 assess current and lifetime Axis-I psychiatric diagnoses, and CAPS<sup>13</sup>, lifetime and past-month  
166 versions, to assess lifetime and past-month WTC-related PTSD diagnostic status and WTC-  
167 related PTSD symptom severity. Lifetime and past-month PTSD diagnosis was defined as  
168 meeting DSM-IV criteria for WTC-related PTSD and a total score  $\geq 40$  on the lifetime and past-  
169 month CAPS, respectively.

170

171 On the same day as the clinical assessment, participants also completed the Childhood Trauma  
172 Questionnaire (CTQ)<sup>20</sup>, assessing physical, sexual, and emotional abuse, and physical and  
173 emotional neglect experienced in childhood; the Traumatic Life Events Questionnaire (TLEQ)<sup>21</sup>,  
174 assessing lifetime exposure to a range of traumatic events (e.g, crime, natural disaster, assault); a



175 checklist of 15 stressful life events they might have experienced since 9/11/2011 (e.g., “lost a  
176 job/laid off/lost income”, “divorced from spouse”, “had debt trouble”), modified from the  
177 Diagnostic Interview Schedule (DIS) Disaster Supplement<sup>22</sup>; and a health questionnaire asking  
178 which medical conditions they had ever been diagnosed with<sup>23</sup>, modified to add common WTC-  
179 related conditions (asthma or chronic respiratory condition, chronic rhinitis or sinusitis, sleep  
180 apnea, or acid reflux). Participants additionally completed a history and physical examination  
181 conducted by a licensed nurse practitioner, as well as routine laboratory testing, to rule out acute  
182 medical illness or exacerbation of chronic medical illness.

183  
184 Among the 355 participants, 108 were determined to have met DSM-IV criteria for lifetime  
185 WTC-related PTSD, with 53 of them still meeting past-month PTSD criteria. The heterogeneity  
186 of PTSD confers some problems when attempting to analyze the disorder by case/control status  
187 alone. Case/control analyses do not fully capture the symptom complexity of the disorder,  
188 resulting in poor genomic modeling. Similarly, while overall PTSD symptom severity is a better  
189 quantitative measurement, it does not fully capture variability across PTSD symptomatology on  
190 a useful clinical level.<sup>24</sup> To address this variability, we examined five symptom dimensions (re-  
191 experiencing, avoidance, emotional numbing, dysphoric arousal and anxious arousal symptoms),  
192 assessed with the CAPS to more accurately examine the heterogeneity of PTSD symptomatology  
193 (Figure 2).<sup>25</sup>

194

### 195 **Blood sample collection and RNA extraction**

196 Participants were instructed to fast after midnight and underwent collection of blood samples  
197 between 8:00 and 10:00 am. Total RNA was purified from whole blood collected in PAXgene

198 blood RNA tubes (Qiagen, Germantown, MD, USA) using a PAXgene blood RNA kit IVD  
199 (Qiagen, Germantown, MD, USA). Total RNA concentration and quality were estimated using a  
200 NanoDrop 200c spectrophotometer according to the manufacturer instructions (Thermo Fisher  
201 Scientific, Waltham, MA, USA). Samples with an optical density ratio 260/280 superior or equal  
202 to 1.8 passed the quality control. Total RNA concentration and quality were also estimated using  
203 an Agilent RNA 6000 nano kit and an Agilent 2100 bioanalyzer according to the manufacturer  
204 instructions (Agilent Technologies, Santa Clara, CA, USA). Samples with an RNA Integrity  
205 Number superior or equal to 7 passed the quality control. RNA samples (derived from blood)  
206 were processed for RNA Seq with polyA selection and sequenced on Illumina HiSeq High  
207 Output mode with a sequencing configuration of 2x150 paired-end reads (GENEWIZ, South  
208 Plainfield, NJ). A total of 10M paired reads per sample was set as a threshold to account for high  
209 globin reads; 29 samples were re-sequenced to meet threshold.

210

### 211 **Gene expression quality control analysis**

212 We processed whole-blood gene expression data using the RAPiD.19 RNA-sequencing pipeline,  
213 and calculated normalized TPM counts from RSEM.<sup>26</sup> We performed quality control analysis on  
214 the counts to verify sequencing and residual contributions to variance using VariancePartition<sup>27</sup>.  
215 We corrected each sequencing batch for sex, age, and genotype-derived principal components  
216 using Limma/voom weighted least-squares linear regression.<sup>28</sup> We rank normalized and  
217 combined the residuals from the linear regression of each batch, and these values were used in all  
218 subsequent association tests for CAPS total score and five PTSD dimension scores (re-  
219 experiencing, avoidance, numbing, dysphoric arousal and anxious arousal).

220

221 **Differential gene expression analysis**

222 We used whole blood RNA-sequencing to test for associations between gene expression and  
223 WTC-related PTSD symptom severity on (i) highest lifetime CAPS score (CAPS<sub>L</sub>), (ii) past-  
224 month CAPS score (CAPS<sub>PM</sub>), and (iii) PTSD dimension scores including re-experiencing,  
225 avoidance, numbing, dysphoric arousal and anxious arousal, correcting for batch and surrogate  
226 variables (Eqn. 1).

227

$$\text{Gene expression} \sim Dx + \text{batch} + \text{surrogate variables}$$

228

229 Equation 1. General equation for gene expression analysis.

230

231 In addition, study participants had a wide range of psychiatric and somatic comorbidities,  
232 including some with substantial shared genetic aetiology and overlapping symptom profiles (e.g.,  
233 major depressive disorder); comorbidities that may represent systemic manifestations of of  
234 PTSD (e.g., cardiovascular disease<sup>29</sup>); and exposure to the dust cloud during and following 9/11.  
235 We expect all of these factors to have substantial impacts on gene expression. Significant co-  
236 linearity between some of these measures and CAPS scores preclude including these variables as  
237 covariates within our analysis, and testing directly for their effect on gene expression (in  
238 particular, due to high correlations between length of time at the WTC site, CAPS score, and  
239 dust-cloud exposure [ref]; and between CAPS score and co-morbid medical disorders potentially  
240 constituting systemic manifestations of PTSD). Instead, in order to test whether these  
241 comorbidities and exposures might account for some of the CAPS-expression associations we  
242 observe, we also tested for gene expression associations with (i) an index of dust cloud

243 exposure<sup>30</sup>; and (ii) number of medical comorbidities. Next, we tested for (i) interaction effects  
244 between each of these measures and CAPS score; (ii) enrichment of genome-wide significant  
245 associations between these measures and CAPS score; and (iii) genome-wide correlations in  
246 association statistics. For all gene expression analyses, we established significance using a  
247 Benjamini-Hochberg<sup>31</sup> FDR correction < 5%.

248

### 249 **Gene-set enrichment of PTSD-associated genes**

250 We tested for gene set enrichment among our genes associated with CAPS<sub>L</sub>, CAPS<sub>PM</sub>, and PTSD  
251 dimension scores by (i) analyzing the significant genes from the association tests for pathway  
252 enrichment by gene permutation testing and (ii) analyzing all genes from the ranked association  
253 test gene lists to subject permutation using the R versions of GSEA<sup>32</sup> and fgsea<sup>33,34</sup>. For gene  
254 permutation testing, we included all nominally significant genes ( $p < 0.05$ ), and tested for  
255 association with 105 gene sets using Kyoto Encyclopedia of Genes and Genomes (KEGG)  
256 database<sup>35</sup> for pathway enrichment.

257

258 We applied phenotype permutation testing rather than gene set permutation to keep the  
259 correlations between the genes in the dataset and the genes in the gene set pathways. For the  
260 subject permutation testing, each test was run with 10000 permutations, and pathways that  
261 passed Benjamini-Hochberg multiple testing correction were considered significantly enriched.  
262 To synthesize this large amount of gene set information, we generated comparative PTSD  
263 symptom plots using Clusterprofiler<sup>36</sup> in R. Comparative gene set plots contained pathways  
264 which passed FDR < 0.05 significance threshold.

265

## 266 **Meta-analysis with existing gene expression analyses**

267 To replicate our gene expression results, we meta-analyzed our data with association statistics  
268 from five other genome-wide gene expression analyses:

- 269 1. **WTC responder study Stony Brook University (SB WTC)**<sup>3</sup>; N=282. Data are divided  
270 into discovery (WTC-d) and replication (WTC-r) cohorts.
- 271 2. **Trauma Mega-Analysis study (TMA)**<sup>12</sup>. TMA combines 7 different PTSD studies and  
272 transformed the expression data into three categories: combat (N=169), male  
273 interpersonal (N=112), and female interpersonal trauma (N=259)<sup>12</sup>. We analyzed these  
274 data as separate trauma studies for the purposes of our meta-analysis (Table 2).

275  
276 Since the majority of studies focus on PTSD case/control status, rather than associations with  
277 continuous CAPS scores (as here), we repeated our analysis to compare gene expression between  
278 PTSD cases (defined as meeting DSM-IV criteria for PTSD and a total CAPS  $\geq$  40) and controls  
279 (all others in our sample).

280  
281 We meta-analyzed PTSD case-control association statistics using a sample-size based meta-  
282 analysis approach in METAL<sup>37</sup>. We included all genes from our analysis that reached  $p < 0.05$   
283 (N=9,380 for past-month and N=1,016 for lifetime) and all available genes from other studies  
284 (N=27-806; Table 2).

## 285 **Cellular deconvolution associated with CAPS scores**

286  
287 We applied CIBERSORT to our raw counts matrix to deconvolute immune cell types in our  
288 patients using the immune cell matrix reference panel LM22<sup>38</sup>. We tested for association  
289 between cell type proportions and CAPS<sub>PM</sub>, CAPS<sub>L</sub>.

290 **Results**

291 **Gene expression is associated with PTSD symptom levels in WTC first responders**

292 We tested for association between expression of 12,220 genes and total CAPS score in a sample  
293 of 355 WTC first responders. We identified 31 genes significantly associated with total past-  
294 month CAPS score (CAPS<sub>PM</sub>; Figure 3), and 66 genes associated with lifetime (highest) CAPS  
295 score (CAPS<sub>L</sub>, Figure 3). Of these, 42/66 genes are associated only with CAPS<sub>L</sub>, (and not  
296 CAPS<sub>PM</sub>), while 7/31 genes were associated only with CAPS<sub>PM</sub>, (and not CAPS<sub>L</sub>). Genome-wide  
297 associations with CAPS<sub>PM</sub> and CAPS<sub>L</sub> were significantly correlated (Beta  $\rho = 0.82$ ,  $p < 2.2 \times 10^{-16}$ ;  
298 FDR-adjusted P-values  $\rho = 0.79$ ,  $p < 2.2 \times 10^{-16}$ ) (Table 3).

299

300 We tested for enrichment of 59 well-studied PTSD candidate genes<sup>11</sup> (Sup. Table 1) within our  
301 association statistics. We did not observe enrichment of these genes within our past-month or  
302 lifetime association analyses ( $p = 0.174$ ,  $0.245$ ). However, of these candidate genes, *SERPINA1*  
303 was significantly associated with CAPS<sub>L</sub> score.

304

305 **Environmental exposure to the WTC dust cloud**

306 Next, we tested whether our genes associated with CAPS scores are specific to PTSD, or are  
307 driven by spurious associations with comorbid diagnoses or environmental exposure to the dust  
308 cloud at Ground Zero. In particular, a number of individuals within our study have comorbid  
309 conditions and complex medical histories (Table 4), including disorders with substantial shared  
310 genetic and environmental etiology with PTSD, and disorders and traits that may present as  
311 systemic manifestations of PTSD.

312

313 First, we tested whether these medical comorbidities alone may account for the associations we  
314 observe; we identified 175 gene associations with an aggregate summary score of medical  
315 comorbidities. Notably, these genes do not include any of our significant associations with CAPS  
316 scores. We identified only one gene, *STX10*, with significant interaction between CAPS scores  
317 and comorbid conditions; that is, gene expression was elevated specifically among individuals  
318 with both high CAPS<sub>L</sub> and a large number of comorbid diagnoses (Figure 4).

319  
320 Next, we tested for association between gene expression and exposure to the dust cloud at  
321 Ground Zero<sup>30</sup>. We identified 561 genes significantly associated with this exposure. We tested  
322 for, but did not find, any significant interactions between CAPS scores and dust cloud exposure  
323 ( $p > 0.05$ ), and did not observe a large correlation of expression results in genome-wide  
324 significant genes between the two analyses for CAPS<sub>PM</sub> or CAPS<sub>L</sub> ( $R^2 = 0.1835$ ,  $R^2 = 0.2466$ ,  
325  $p < 0.05$ ) (Figure 4). Together, these analyses imply that our gene-CAPS score associations are  
326 specific and relevant to PTSD, rather than due to confounding by comorbid diagnoses or dust  
327 cloud exposure.

328

### 329 **Gene expression analysis reveals PTSD dimension-specific associations**

330 Next, we tested for gene expression associations with past-month and lifetime PTSD symptom  
331 dimensions (re-experiencing, avoidance, dysphoric arousal, anxious arousal, numbing; Sup.  
332 Table 2).

333 Our analysis revealed overlapping and unique genes for each symptom dimension, and  
334 significant correlation of genome-wide association statistics between symptom dimensions.

335 In particular, both our past-month and lifetime analyses identified a large number of genes (61  
336 and 82, respectively; Sup. Table 2) associated with anxious arousal, including many genes not  
337 associated with any other phenotype in our analysis (16, 27, respectively). By contrast, although  
338 we identified a substantial number of genes significantly associated with dysphoric arousal (20,  
339 16 for past-month and lifetime respectively), only two genes were uniquely associated with this  
340 phenotype (1 gene in past-month; 2 in lifetime). Only one gene, *COPE*, was significantly  
341 associated with every phenotype tested in our analysis. A second gene, *EIF4A1*, was also  
342 significantly associated with every lifetime (highest) phenotype (Figure 5).

343

#### 344 **PTSD pathway enrichment demonstrates immune, psychiatric, and metabolic relationships**

345 Our genetic enrichment and pathway analyses identified well-established PTSD mechanisms and  
346 pathways, including pathways associated with inflammation, neurological signaling pathways,  
347 structural remodeling within and between cells, and HPA-axis and signaling<sup>39-44</sup>. Based on our  
348 KEGG pathway enrichment analysis, we revealed a set of genes significantly associated with  
349 psychiatric disorders pathways that were significantly enriched in our results: *FURIN*, *PPP2R1A*,  
350 *GNAI2*, *PCLB2*, and *GNB2*. The two symptoms that we discovered were associated with *FURIN*  
351 and their FDR-corrected p-values were avoidance (p=0.028, B=2.55) and numbing (p=0.034,  
352 B=-0.009). *PPP2R1A* was associated with anxious arousal (p=0.009, B=2.60). *PCLB2* was only  
353 associated with numbing (p=0.046, B=-0.952). *GNAI2* was associated with anxious arousal  
354 (p=0.042, B=-0.780) and numbing (p=0.047, B=-1.03), and *GNB2* was only associated with  
355 avoidance (p=0.036, B=1.130) (Figure 6).

356



357 Immunological and metabolic gene enrichment was consistent across CAPS<sub>L</sub> score and numbing,  
358 but was less pronounced in anxious arousal. For past-month analyses, immune function was most  
359 associated with anxious arousal, whereas metabolic function was enriched in CAPS<sub>PM</sub>, and  
360 numbing, to a lesser extent. For both lifetime and past-month scores, neurological signaling  
361 pathways were most significantly pronounced in numbing, and were less prevalent in the overall  
362 total CAPS score analysis. For lifetime scores, structural pathway enrichment was significantly  
363 higher in total CAPS score, anxious arousal, and numbing, whereas for past-month scores,  
364 structural enrichment was most associated with anxious arousal (Figure 6).

365

### 366 **Meta-analysis prioritizes 10 genes associated with PTSD**

367 We sought to replicate our associations with previous PTSD studies. Since the majority of  
368 publicly available PTSD gene expression analyses follow a case-control, rather than quantitative  
369 measure (CAPS score) analysis, we converted our continuous CAPS<sub>PM</sub> and CAPS<sub>L</sub> values to  
370 PTSD case/control using (CAPS<sub>L</sub> ≥ 40) and DSM-IV PTSD-criteria, and repeated our analysis.  
371 Our case/control and CAPS score association statistics were significantly correlated ( $\rho=0.72$ ,  
372  $p<2.2\times 10^{-16}$ ,  $\rho=0.79$ ,  $p<2.2\times 10^{-16}$ ); however, we note a substantial decrease in the number of  
373 significantly associated genes when using a case-control design, compared to our initial  
374 quantitative analysis, as we would expect<sup>16</sup>. Twelve genes were significant for past-month PTSD  
375 (PTSD<sub>PM</sub>) case/control and 22 genes were significant for lifetime PTSD (PTSD<sub>L</sub>) case/control,  
376 versus 31 genes for CAPS<sub>PM</sub> and 66 genes for CAPS<sub>L</sub>.

377

378 We meta-analyzed our results with five publicly available cohorts (N=739 cases, 438 controls);  
379 two including WTC responders, and three including combat and interpersonal trauma (Table 2).

380 For PTSD<sub>PM</sub> we identified 5 significant genes –*COPE*, *CIRBP*, *FCGRT*, *NACA*, and *ZNF429*  
381 ( $p < 5.33 \times 10^{-6}$ )–, and for PTSD<sub>L</sub> 8 significant genes –*COPE*, *CIRBP*, *TMSB10*, *FCGRT*, *CLIC1*,  
382 *RPS6KB2*, *HNRNPUL1* and *ALDOA* ( $p < 4.92 \times 10^{-5}$ )–, including genes associated with  
383 inflammation and immune response (Figure 7). Of these 10 genes, only one (*COPE*) had  
384 significant heterogeneity of effect size between cohorts: our study and TMA-combat. Three  
385 further genes were unique to our study; *NACA*  $p = 3.34 \times 10^{-6}$ , *CLIC1*,  $p = 1.9 \times 10^{-5}$ , and *HNRNPUL1*  
386  $p = 4.08 \times 10^{-5}$  (Figure 7). The remaining six genes were significant across multiple studies in our  
387 meta-analysis, with highly consistent (negative) direction of effect (i.e., consistently decreased  
388 expression in cases compared to controls): *ZNF439* ( $p = 4.78 \times 10^{-6}$ ), *CIRBP* ( $p = 1.29 \times 10^{-6}$ ),  
389 *TMSB10* ( $p = 6.31 \times 10^{-6}$ ), *FCGRT* ( $p = 1.12 \times 10^{-5}$ ), *RPS6KB2* ( $p = 3.47 \times 10^{-5}$ ), and *ALDOA* ( $p = 4.66$   
390  $\times 10^{-5}$ ) (Table 5).

391

### 392 **Cellular deconvolution identifies differences in cell populations between responders with** 393 **PTSD and controls**

394 Since many of our PTSD-associated genes are related to immune function, we tested whether  
395 immune cell type proportions were correlated with CAPS scores in individuals in our sample.  
396 We performed cell-type deconvolution to identify cell-type proportions for 22 cell types across  
397 all 355 individuals in our sample. We found significant increase of CD4 naïve T cell ( $p < 0.0049$ )  
398 proportions with CAPS<sub>PM</sub>, and significant increase of eosinophils ( $p < 0.042$ ) and CD4 memory  
399 resting T cells ( $p < 0.044$ ) associated with CAPS<sub>L</sub>. In addition, we found significant decrease of  
400 activated natural killer cells ( $p < 0.040$ ) associated with CAPS<sub>L</sub> (Figure 8).

401

## 402 Discussion

403 Although trauma is ubiquitous as a human experience, the types of traumatic experiences vary  
404 greatly among individuals. Our study sample and design present a unique opportunity to examine  
405 gene expression and PTSD symptoms related to a particular traumatic experience, the 9/11 WTC  
406 disaster and its aftermath. To our knowledge, ours is the largest single-traumatic event gene  
407 expression dataset to date. Using CAPS score as a quantitative measure of WTC-related PTSD  
408 symptom severity, we found 66 genes associated with lifetime (highest) CAPS score and 31  
409 genes associated with past-month CAPS score. We additionally found interaction between  
410 CAPS<sub>L</sub> and one gene, *STX10*, in medical comorbidities. Pathway analysis links our associated  
411 genes to metabolic, immunological, structural, and neurological pathways. In addition, we found  
412 10 genes associated with lifetime and past-month PTSD: *COPE*, *CIRBP*, and *FCGRT* shared  
413 between the two; *NACA* and *ZNF429* specific to past-month PTSD; and *TMSB10*, *CLIC1*,  
414 *RPS6KB2*, *HNRNPUL1* and *ALDOA* specific to lifetime PTSD. Furthermore, cellular analysis of  
415 our cohort demonstrated an enrichment in CD4 T cells and eosinophils in responders with PTSD.  
416 Additionally, natural killer cells were decreased in these patients. Our findings support previous  
417 studies which tie together the immune system and PTSD as a systemic disease. Ultimately, these  
418 results represent an additional wealth of knowledge to help understand the genetic expression  
419 and biological etiology of PTSD and uncover potential biomarkers for the disease.

420

421 Examining both lifetime and past-month CAPS scores allowed us to look at not only chronic  
422 effects of PTSD but longevity of the outcomes. While CAPS<sub>PM</sub> is considered the standard for  
423 case/control analysis, looking at both CAPS<sub>L</sub> and CAPS<sub>PM</sub> allows us to ask more specific  
424 questions about the role and relevance of elevated gene expression in PTSD. For example, genes

425 associated with CAPS<sub>PM</sub> might represent current expression changes in PTSD, while those  
426 associated with CAPS<sub>L</sub> (lifetime CAPS score representing, for each responder, the highest WTC-  
427 related PTSD symptom levels ever reached since 9/11/2011) may represent long-lasting  
428 expression changes resulting from lifetime PTSD.

429

430 We identified genes associated with past-month and lifetime CAPS scores that have been  
431 associated with other psychiatric disorders, such as major depressive disorder, schizophrenia and  
432 autism: *FURIN*, *PPP2R1A*, *PLCB2*, *GNAI2*, and *GNB2* (Figure 6)<sup>45-57</sup>. We additionally  
433 identified a group of genes as significantly associated with several lifetime and past-month  
434 PTSD symptom dimensions (*SERPINA1*, *RPS6KAI*, and *STAT3*) that have been previously  
435 linked to PTSD pathophysiology<sup>1,27-31</sup>, and genes associated specifically with anxious arousal  
436 that have been previously associated with anxiety disorders: *DCTN1*, and *FLII*<sup>58,59</sup>. One gene in  
437 our study, *COPE*, was associated with every PTSD phenotype in this analysis. Until now, *COPE*  
438 has not been well studied in the context of psychiatric disorders<sup>60</sup>, but it has been implicated in  
439 the context of Alzheimer's disease<sup>61,62</sup>. Canonically, the COPE protein is the epsilon subunit of  
440 the coatamer protein complex I (COPI) which regulates endocytosis from the plasma membrane  
441 and is involved in Golgi-to-lysosome transportation. Other subunits of COPI have been  
442 implicated in hereditary diseases that cause microcephaly and in autoimmune disorders<sup>63-65</sup>.

443

444 Importantly, our analytical design allowed us to test for potential confounding effects of  
445 comorbidities and environmental exposures<sup>66,67</sup>. We expected many of these comorbidities and  
446 exposures to have a significant impact on gene expression, particularly as some comorbidities  
447 may be more recently occurring than, for example, the highest CAPS<sub>L</sub> measure. Therefore, we

448 tested directly for genes associated with (i) comorbidities and (ii) dust cloud exposure. Although  
449 we identified a large number of genes associated with each phenotype, we note that our  
450 associations do not overlap with our top PTSD genes; we did not observe significant enrichment  
451 of shared associations, and only observed one gene with significant interaction effect between  
452 comorbidities and CAPS<sub>L</sub>. Therefore, we conclude that our results are not confounded by these  
453 exposures; our gene associations are specific to PTSD rather than broadly corresponding to  
454 exposure or general ill-health.

455  
456 KEGG enrichment of our associated genes determined genetic changes in metabolic,  
457 immunological, structural, and neurological pathways associated with total CAPS, numbing, and  
458 anxious arousal phenotypes (Figure 7). Anxious arousal and numbing tend to have few  
459 significantly associated genes in common, while both past-month and lifetime CAPS scores  
460 display a few unique genes but many shared ones. *GNAI2*, while associated with many numbing-  
461 related pathways (long-term depression, oxytocin signaling, etc.), is also significantly associated  
462 with some peripheral anxious arousal-related and CAPS<sub>L</sub>-related pathways (leukocyte migration,  
463 and chemokine signaling, respectively). On the other hand, anxious arousal is uniquely  
464 associated with genes such as *HGS*, *ARFGAP2* and *RAB7A*, which are linked to endocytosis and  
465 immunity. Similarly, our past-month and lifetime CAPS phenotypes are uniquely associated with  
466 glycolysis/gluconeogenesis for genes *ALDOA*, *GAPDH*, *ENO1*, *TP11*, and *PKM*, which may play  
467 roles in HPA-axis or metabolic dysregulation (Table 4).

468  
469 Our analyses identified 10 genes reaching genome-wide significance. Of these, 3/10 (*NACA*  
470  $p=3.34 \times 10^{-6}$ , *CLIC1*,  $p=1.9 \times 10^{-5}$ , and *HNRNPUL1*  $p=4.08 \times 10^{-5}$ ) are specific to our study; all

471 three are downregulated in WTC responders with PTSD compared to controls. *NACA* has been  
472 previously studied as a potential biomarker for depression in mice under stress conditions<sup>68</sup>. The  
473 function of *HNRNPUL1* is relatively unknown. Studies have suggested it might play a role in  
474 DNA damage repair and nucleocytoplasmic RNA transport. *CLICI* has been implicated in other  
475 psychiatric disorders, but its primary function is inflammasome regulation<sup>69-71</sup>. In addition, 6/10  
476 genes had highly consistent directions of effect. These include *FCGRT* ( $p=1.12 \times 10^{-5}$ ), which has  
477 been characterized as an immune regulator of dendritic cell cross-presentation of IgG immune  
478 complexes, necessary to activate a cytotoxic T-cell response and clear antigens<sup>72</sup>. Our analysis  
479 demonstrates a down-regulation of *FCGRT* in WTC responders with PTSD, suggesting reduced  
480 IgG immune complex clearance in these patients (Figure 6).

481  
482 There is evidence that macro- and micro-level physiological damage is a fundamental component  
483 of PTSD, as well as cytoskeletal restructuring for fear-based memory formation in the  
484 amygdala<sup>43,44</sup>. In this study we observed decreased expression in *CIRBP* ( $p= 1.29 \times 10^{-6}$ ), a protein  
485 that traditionally regulates stress and apoptosis under conditions of extreme cold (Figure 6). Its  
486 role as a potential biomarker has been previously explored for different psychiatric disorders<sup>73,74</sup>.  
487 The decrease observed in *TMSB10* expression also contributes to the dysregulation of apoptosis.  
488 *TMSB10* is a pro-apoptotic protein that has been previously associated with downregulation of  
489 gene expression after trauma exposure<sup>3,75,76</sup>. In our meta-analysis, the directionality of effect  
490 ( $p < 2.2 \times 10^{-16}$ ) for each gene was decreased, consistent with PTSD pathophysiology<sup>77,78</sup>.

491  
492 Since many of our PTSD-associated genes are related to immune function, we tested for the  
493 enrichment of immune cell types in our study. We found an overall enrichment of CD4-positive

494 T cells for both past-month and lifetime CAPS scores (Figure 7), consistent with previous  
495 studies<sup>79,80</sup>, including among WTC responders<sup>8</sup>. In addition to CD4 T cell enrichment, our study  
496 also found enrichment in eosinophils and a decrease in natural killer cells for CAPS<sub>L</sub> (Figure 7).  
497 These cellular diversities may point to a higher inflammatory signature in PTSD, particularly in  
498 the case of CD4 T cell enrichment. It has been well demonstrated that dysregulation of CD4 T  
499 cells leads to autoimmune activation<sup>81</sup>, and in combination with an increase in eosinophils can  
500 lead to an inflammatory cascade in patients. There is strong evidence that PTSD is associated  
501 with a pro-inflammatory state, which our findings support<sup>82-86</sup>.

502  
503 While our study provides an in-depth look at the genetic expression and outcomes related to a  
504 specific traumatic experience, we note some significant caveats. Our expression analysis was  
505 limited to blood, but should be expanded to other tissues in the future, such as the brain.  
506 Similarly, our analysis was restricted to whole blood, but a more in-depth single cell analysis  
507 will be critical to determine gene expression in individual cell types. In addition, we note that our  
508 cohort includes a significant proportion of individuals who have self-selected into high-risk  
509 professions. As such, we expect a higher lifetime exposure to stressful situations, including  
510 potentially many other life-threatening scenarios. It is likely that the PTSD symptoms observed  
511 here are at least partially accounted for by other traumas and stressors, even though upon CAPS  
512 administration, study clinicians specifically inquired about WTC-related PTSD symptoms.  
513 Conversely, the high-risk nature of these individuals' occupations may also mean increased  
514 exposure to resilience training for a sizable subsample, and greater access to social support  
515 networks of peers with similar experiences, potentially providing protective mechanisms.

516

517 In conclusion, this study has identified a vast number of biomarkers that will be potentially  
518 useful tools after independent validation. In particular, ten of these genes stand out as  
519 reproducible across multiple studies and should be considered as high priority. In combination  
520 with pathway and cellular deconvolution results, these findings highlight a strong connection  
521 with immune dysregulation and other psychiatric illnesses. We believe that future studies should  
522 focus on validation of our PTSD-associated genes and also single-cell RNA-sequencing  
523 approaches to delineate the role of immune cell types in PTSD.



524 **References**

- 525 1. Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I  
526 Disorders (SCID). *N. Y. State Psychiatr. Inst. Biom. Res. N. Y.* (1995).
- 527 2. Yehuda, R. *et al.* Gene Expression Patterns Associated with Posttraumatic Stress Disorder  
528 Following Exposure to the World Trade Center Attacks. *Biol. Psychiatry* **66**, 708–711 (2009).
- 529 3. Kuan, P.-F. *et al.* Gene expression associated with PTSD in World Trade Center responders:  
530 An RNA sequencing study. *Transl. Psychiatry* **7**, 1297 (2017).
- 531 4. Clouston, S. *et al.* Traumatic exposures, posttraumatic stress disorder, and cognitive  
532 functioning in World Trade Center responders. *Alzheimers Dement. N. Y. N* **3**, 593–602  
533 (2017).
- 534 5. Clouston, S. A. P. *et al.* Posttraumatic stress disorder and total amyloid burden and amyloid-  
535  $\beta$  42/40 ratios in plasma: Results from a pilot study of World Trade Center responders.  
536 *Alzheimers Dement. Amst. Neth.* **11**, 216–220 (2019).
- 537 6. Clouston, S. A. P. *et al.* Incidence of mild cognitive impairment in World Trade Center  
538 responders: Long-term consequences of re-experiencing the events on 9/11/2001.  
539 *Alzheimers Dement. Diagn. Assess. Dis. Monit.* **11**, 628–636 (2019).
- 540 7. Gong, Y. *et al.* Prostate Cancer in World Trade Center Responders Demonstrates Evidence  
541 of an Inflammatory Cascade. *Mol. Cancer Res.* **17**, 1605–1612 (2019).
- 542 8. Kuan, P.-F. *et al.* Cell type-specific gene expression patterns associated with posttraumatic  
543 stress disorder in World Trade Center responders. *Transl. Psychiatry* **9**, 1–11 (2019).
- 544 9. Kuan, P.-F. *et al.* Enhanced exposure assessment and genome-wide DNA methylation in  
545 World Trade Center disaster responders. *Eur. J. Cancer Prev.* **28**, 225–233 (2019).

- 546 10. Sarapas, C. *et al.* Genetic Markers for PTSD Risk and Resilience Among Survivors of the  
547 World Trade Center Attacks. *Dis. Markers* **30**, 101–110 (2011).
- 548 11. Huckins, L. M. *et al.* Analysis of Genetically Regulated Gene Expression identifies a trauma  
549 type specific PTSD gene, SNRNP35. *bioRxiv* 581124 (2019) doi:10.1101/581124.
- 550 12. Breen, M. S. *et al.* PTSD Blood Transcriptome Mega-Analysis: Shared Inflammatory  
551 Pathways across Biological Sex and Modes of Trauma. *Neuropsychopharmacology* **43**, 469–  
552 481 (2018).
- 553 13. Blake DD, Weathers FW, Nagy LM, et al. The development of a Clinician-Administered PTSD  
554 Scale. *J Trauma Stress* **8(1)**, 75–90 (1995).
- 555 14. Fanous, A. H. & Kendler, K. S. Genetic heterogeneity, modifier genes, and quantitative  
556 phenotypes in psychiatric illness: searching for a framework. *Mol. Psychiatry* **10**, 6–13  
557 (2005).
- 558 15. Schijven, D. *et al.* Multivariate genome-wide analysis of stress-related quantitative  
559 phenotypes. *Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol.* **29**, 1354–  
560 1364 (2019).
- 561 16. Lee, S. H. & Wray, N. R. Novel Genetic Analysis for Case-Control Genome-Wide Association  
562 Studies: Quantification of Power and Genomic Prediction Accuracy. *PLoS ONE* **8**, (2013).
- 563 17. Dasaro, C. R. *et al.* Cohort Profile: World Trade Center Health Program General Responder  
564 Cohort. *Int. J. Epidemiol.* **46**, e9 (2017).
- 565 18. Ruggiero, K. J., Del Ben, K., Scotti, J. R. & Rabalais, A. E. Psychometric properties of the PTSD  
566 Checklist-Civilian Version. *J. Trauma. Stress* **16**, 495–502 (2003).

- 567 19. Huckins, L. M. *et al.* Polygenic regulation of PTSD severity and outcomes among World  
568 Trade Center responders. *medRxiv* 2020.12.06.20244772 (2020)  
569 doi:10.1101/2020.12.06.20244772.
- 570 20. Bernstein, D. P. *et al.* Development and validation of a brief screening version of the  
571 Childhood Trauma Questionnaire. *Child Abuse Negl.* **27**, 169–190 (2003).
- 572 21. Kubany, E. S. *et al.* Development and preliminary validation of a brief broad-spectrum  
573 measure of trauma exposure: the Traumatic Life Events Questionnaire. *Psychol. Assess.* **12**,  
574 210–224 (2000).
- 575 22. North, CS., et al. The Diagnostic Interview Schedule/Disaster Supplement (DIS-IV/DS). *St*  
576 *Louis Wash. Univ.* (2001).
- 577 23. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Medical comorbidity of full  
578 and partial posttraumatic stress disorder in US adults: results from Wave 2 of the National  
579 Epidemiologic Survey on Alcohol and Related Conditions. *Psychosom. Med.* **73**, 697–707  
580 (2011).
- 581 24. Horn, S. R. *et al.* Latent typologies of posttraumatic stress disorder in World Trade Center  
582 responders. *J. Psychiatr. Res.* **83**, 151–159 (2016).
- 583 25. Pietrzak, R. H., Tsai, J., Harpaz-Rotem, I., Whealin, J. M. & Southwick, S. M. Support for a  
584 novel five-factor model of posttraumatic stress symptoms in three independent samples of  
585 Iraq/Afghanistan veterans: a confirmatory factor analytic study. *J. Psychiatr. Res.* **46**, 317–  
586 322 (2012).
- 587 26. Shah, H., Wang, Y.-C., Castellanos, R., Pandya, C., & Giles, Z. RAPiD - An Agile and  
588 Dependable RNA-Seq Framework. *ASHG 2015* (2015).

- 589 27. Hoffman, G. E. & Schadt, E. E. variancePartition: interpreting drivers of variation in complex  
590 gene expression studies. *BMC Bioinformatics* **17**, 483 (2016).
- 591 28. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model  
592 analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
- 593 29. Mellon, S. H., Gautam, A., Hammamieh, R., Jett, M. & Wolkowitz, O. M. Metabolism,  
594 Metabolomics, and Inflammation in Posttraumatic Stress Disorder. *Biol. Psychiatry* **83**, 866–  
595 875 (2018).
- 596 30. Wisnivesky, J. P. *et al.* Persistence of multiple illnesses in World Trade Center rescue and  
597 recovery workers: a cohort study. *Lancet Lond. Engl.* **378**, 888–897 (2011).
- 598 31. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful  
599 Approach to Multiple Testing. *J. R. Stat. Soc. Ser. B Methodol.* **57**, 289–300 (1995).
- 600 32. Bild, A. & Febbo, P. G. Application of a priori established gene sets to discover biologically  
601 important differential expression in microarray data. *Proc. Natl. Acad. Sci.* **102**, 15278–  
602 15279 (2005).
- 603 33. Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. *bioRxiv*  
604 060012 (2019) doi:10.1101/060012.
- 605 34. How to do GSEA in R with (fgsea or gage) and plot results. *Bioinformatics Breakdown*  
606 <https://bioinformaticsbreakdown.com/how-to-gsea/> (2019).
- 607 35. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference  
608 resource for gene and protein annotation. *Nucleic Acids Res.* **44**, D457–D462 (2016).
- 609 36. Yu, G., Wang, L.-G., Han, Y. & He, Q.-Y. clusterProfiler: an R Package for Comparing  
610 Biological Themes Among Gene Clusters. *OMICS J. Integr. Biol.* **16**, 284–287 (2012).

- 611 37. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide  
612 association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 613 38. Newman, A. M. *et al.* Robust enumeration of cell subsets from tissue expression profiles.  
614 *Nat. Methods* **12**, 453–457 (2015).
- 615 39. Daskalakis, N. P., Rijal, C. M., King, C., Huckins, L. M. & Ressler, K. J. Recent Genetics and  
616 Epigenetics Approaches to PTSD. *Curr. Psychiatry Rep.* **20**, 30 (2018).
- 617 40. Neigh, G. N. & Ali, F. F. Co-Morbidity of PTSD and Immune System Dysfunction:  
618 Opportunities for Treatment. *Curr. Opin. Pharmacol.* **29**, 104–110 (2016).
- 619 41. Wang, Z., Caughron, B. & Young, M. R. I. Posttraumatic Stress Disorder: An Immunological  
620 Disorder? *Front. Psychiatry* **8**, (2017).
- 621 42. Speer, K. E., Semple, S., Naumovski, N., D’Cunha, N. M. & McKune, A. J. HPA axis function  
622 and diurnal cortisol in post-traumatic stress disorder: A systematic review. *Neurobiol. Stress*  
623 **11**, (2019).
- 624 43. Yehuda, R. *et al.* Post-traumatic stress disorder. *Nat. Rev. Dis. Primer* **1**, 1–22 (2015).
- 625 44. Nutt, D. J. & Malizia, A. L. Structural and functional brain changes in posttraumatic stress  
626 disorder. *J. Clin. Psychiatry* **65 Suppl 1**, 11–17 (2004).
- 627 45. Duncan, L. E. *et al.* Largest GWAS of PTSD (N=20,070) yields genetic overlap with  
628 schizophrenia and sex differences in heritability. *Mol. Psychiatry* **23**, 666–673 (2018).
- 629 46. Li, Z. *et al.* Genome-wide association analysis identifies 30 new susceptibility loci for  
630 schizophrenia. *Nat. Genet.* **49**, 1576–1583 (2017).
- 631 47. Jong, S. de *et al.* Immune signatures and disorder-specific patterns in a cross-disorder gene  
632 expression analysis. *Br. J. Psychiatry* **209**, 202–208 (2016).

- 633 48. Tsolakidou, A. *et al.* Gene expression profiling in the stress control brain region  
634 hypothalamic paraventricular nucleus reveals a novel gene network including Amyloid beta  
635 Precursor Protein. *BMC Genomics* **11**, 546 (2010).
- 636 49. Maccarrone, G. *et al.* Psychiatric patient stratification using biosignatures based on  
637 cerebrospinal fluid protein expression clusters. *J. Psychiatr. Res.* **47**, 1572–1580 (2013).
- 638 50. Hou, Y. *et al.* Schizophrenia-associated rs4702 G allele-specific downregulation of FURIN  
639 expression by miR-338-3p reduces BDNF production. *Schizophr. Res.* **199**, 176–180 (2018).
- 640 51. Schrode, N. *et al.* Synergistic effects of common schizophrenia risk variants. *Nat. Genet.* **51**,  
641 1475–1485 (2019).
- 642 52. English, J. A. *et al.* Reduced protein synthesis in schizophrenia patient-derived olfactory  
643 cells. *Transl. Psychiatry* **5**, e663–e663 (2015).
- 644 53. Miron, J. *et al.* Association of PPP2R1A with Alzheimer’s disease and specific cognitive  
645 domains. *Neurobiol. Aging* **81**, 234–243 (2019).
- 646 54. Bralten, J. *et al.* Candidate Genetic Pathways for Attention-Deficit/Hyperactivity Disorder  
647 (ADHD) Show Association to Hyperactive/Impulsive Symptoms in Children With ADHD. *J.*  
648 *Am. Acad. Child Adolesc. Psychiatry* **52**, 1204-1212.e1 (2013).
- 649 55. Chang, W.-S., Wang, Y.-H., Zhu, X.-T. & Wu, C.-J. Genome-Wide Profiling of miRNA and  
650 mRNA Expression in Alzheimer’s Disease. *Med. Sci. Monit. Int. Med. J. Exp. Clin. Res.* **23**,  
651 2721–2731 (2017).
- 652 56. Kawai, T. *et al.* Gene expression signature in peripheral blood cells from medical students  
653 exposed to chronic psychological stress. *Biol. Psychol.* **76**, 147–155 (2007).

- 654 57. Zhao, Y. *et al.* A large-scale integrative analysis of GWAS and common meQTLs across whole  
655 life course identifies genes, pathways and tissue/cell types for three major psychiatric  
656 disorders. *Neurosci. Biobehav. Rev.* **95**, 347–352 (2018).
- 657 58. Konno, T. *et al.* DCTN1-related neurodegeneration: Perry syndrome and beyond.  
658 *Parkinsonism Relat. Disord.* **41**, 14–24 (2017).
- 659 59. Seth, A., Giunta, S., Franceschil, C., Kola, I. & Venanzoni, M. C. Regulation of the human  
660 stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. *Cell Death*  
661 *Differ.* **6**, 902–907 (1999).
- 662 60. St-Louis, É. *et al.* Involvement of the coatmer protein complex I in the intracellular traffic  
663 of the delta opioid receptor. *Mol. Cell. Neurosci.* **79**, 53–63 (2017).
- 664 61. Bettayeb, K. *et al.* Relevance of the COPI complex for Alzheimer’s disease progression in  
665 vivo. *Proc. Natl. Acad. Sci. U. S. A.* **113**, 5418–5423 (2016).
- 666 62. Yang, Y., Wang, X., Ju, W., Sun, L. & Zhang, H. Genetic and Expression Analysis of COPI  
667 Genes and Alzheimer’s Disease Susceptibility. *Front. Genet.* **10**, 866 (2019).
- 668 63. Izumi, K. *et al.* ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-  
669 Mediated Transport Defects. *Am. J. Hum. Genet.* **99**, 451–459 (2016).
- 670 64. Watkin, L. B. *et al.* COPA mutations impair ER-Golgi transport and cause hereditary  
671 autoimmune-mediated lung disease and arthritis. *Nat. Genet.* **47**, 654–660 (2015).
- 672 65. Jean, F., Stuart, A. & Tarailo-Graovac, M. Dissecting the Genetic and Etiological Causes of  
673 Primary Microcephaly. *Front. Neurol.* **11**, (2020).

- 674 66. Lippmann, M., Cohen, M. D. & Chen, L.-C. Health effects of World Trade Center (WTC) Dust:  
675 An unprecedented disaster with inadequate risk management. *Crit. Rev. Toxicol.* **45**, 492–  
676 530 (2015).
- 677 67. Reibman, J. *et al.* Characteristics of a Residential and Working Community With Diverse  
678 Exposure to World Trade Center Dust, Gas, and Fumes. *J. Occup. Environ. Med. Am. Coll.*  
679 *Occup. Environ. Med.* **51**, 534–541 (2009).
- 680 68. Hervé, M. *et al.* Translational Identification of Transcriptional Signatures of Major  
681 Depression and Antidepressant Response. *Front. Mol. Neurosci.* **10**, (2017).
- 682 69. Carlini, V. *et al.* CLIC1 Protein Accumulates in Circulating Monocyte Membrane during  
683 Neurodegeneration. *Int. J. Mol. Sci.* **21**, (2020).
- 684 70. Tang, T. *et al.* CLICs-dependent chloride efflux is an essential and proximal upstream event  
685 for NLRP3 inflammasome activation. *Nat. Commun.* **8**, 202 (2017).
- 686 71. Gurunathan, G., Yu, Z., Coulombe, Y., Masson, J.-Y. & Richard, S. Arginine methylation of  
687 hnRNPUL1 regulates interaction with NBS1 and recruitment to sites of DNA damage. *Sci.*  
688 *Rep.* **5**, 10475 (2015).
- 689 72. Baker, K. *et al.* Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG  
690 immune complexes by CD8–CD11b+ dendritic cells. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 9927–  
691 9932 (2011).
- 692 73. Le-Niculescu, H. *et al.* Towards precision medicine for stress disorders: diagnostic  
693 biomarkers and targeted drugs. *Mol. Psychiatry* **25**, 918–938 (2020).
- 694 74. Zhu, X., Bühner, C. & Wellmann, S. Cold-inducible proteins CIRP and RBM3, a unique couple  
695 with activities far beyond the cold. *Cell. Mol. Life Sci.* **73**, 3839–3859 (2016).



- 696 75. Zhou, J.-Y. *et al.* Trauma-associated Human Neutrophil Alterations Revealed by Comparative  
697 Proteomics Profiling. *Proteomics Clin. Appl.* **7**, (2013).
- 698 76. Lu, Q., Shen, N., Li, X. M. & Chen, S. L. Genomic view of IFN- $\alpha$  response in pre-autoimmune  
699 NZB/W and MRL/lpr mice. *Genes Immun.* **8**, 590–603 (2007).
- 700 77. Chen, Y., Li, X., Kobayashi, I., Tsao, D. & Mellman, T. A. Expression and methylation in  
701 posttraumatic stress disorder and resilience; evidence of a role for odorant receptors.  
702 *Psychiatry Res.* **245**, 36–44 (2016).
- 703 78. Breen, M. S. *et al.* Differential transcriptional response following glucocorticoid activation in  
704 cultured blood immune cells: a novel approach to PTSD biomarker development. *Transl.*  
705 *Psychiatry* **9**, 201 (2019).
- 706 79. Glover, D. A., Steele, A. C., Stuber, M. L. & Fahey, J. L. Preliminary evidence for lymphocyte  
707 distribution differences at rest and after acute psychological stress in PTSD-symptomatic  
708 women. *Brain. Behav. Immun.* **19**, 243–251 (2005).
- 709 80. Lemieux, A., Coe, C. L. & Carnes, M. Symptom severity predicts degree of T cell activation in  
710 adult women following childhood maltreatment. *Brain. Behav. Immun.* **22**, 994–1003  
711 (2008).
- 712 81. Skapenko, A., Leipe, J., Lipsky, P. E. & Schulze-Koops, H. The role of the T cell in autoimmune  
713 inflammation. *Arthritis Res. Ther.* **7**, S4–S14 (2005).
- 714 82. Baumeister, D., Akhtar, R., Ciufolini, S., Pariante, C. M. & Mondelli, V. Childhood trauma and  
715 adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and  
716 tumour necrosis factor- $\alpha$ . *Mol. Psychiatry* **21**, 642–649 (2016).

- 717 83. Dong, Y. *et al.* Stress-induced NLRP3 inflammasome activation negatively regulates fear  
718 memory in mice. *J. Neuroinflammation* **17**, 205 (2020).
- 719 84. Fonkoue, I. T. *et al.* Symptom severity impacts sympathetic dysregulation and inflammation  
720 in post-traumatic stress disorder (PTSD). *Brain. Behav. Immun.* **83**, 260–269 (2020).
- 721 85. Michopoulos, V., Powers, A., Gillespie, C. F., Ressler, K. J. & Jovanovic, T. Inflammation in  
722 Fear- and Anxiety-Based Disorders: PTSD, GAD, and Beyond. *Neuropsychopharmacology* **42**,  
723 254–270 (2017).
- 724 86. Speer, K., Upton, D., Semple, S. & McKune, A. Systemic low-grade inflammation in post-  
725 traumatic stress disorder: a systematic review. *J. Inflamm. Res.* **11**, 111–121 (2018).
- 726

**Table 1. Demographic and Other Characteristics**

	Mean (SD) or N (%)	
Age (years)	54.1 (8.3)	<i>Mean (SD)</i>
Number of years post-9/11 sample collected	13 (2.3)	<i>Mean (SD)</i>
BMI	30.1 (5.9)	<i>Mean (SD)</i>
Male sex	291 (82)	<i>N (%)</i>
Current smoker	22 (6.2)	<i>N (%)</i>
High school graduate	301 (84.9)	<i>N (%)</i>
Annual income > \$90,000	178 (50.1)	<i>N (%)</i>
Responder type		
Police responder	145 (40.8)	<i>N (%)</i>
Non-traditional responder	210 (59.2)	<i>N (%)</i>
Race-ethnicity		
African American	64 (18)	<i>N (%)</i>
Asian	5 (1.4)	<i>N (%)</i>
Hispanic	72 (20.3)	<i>N (%)</i>
Native American	9 (2.5)	<i>N (%)</i>
European American (White)	216 (60.8)	<i>N (%)</i>
Other	8 (2.3)	<i>N (%)</i>

Note: SD = standard deviation; BMI= body mass index; n=355

**Table 2. Gene Expression Studies Included in Meta-Analysis**

<b>Trauma Study</b>	<b>ISMMS</b>	<b>WTC-d<sup>3</sup></b>	<b>WTC-r<sup>3</sup></b>	<b>TMA-C<sup>12</sup></b>	<b>TMA-MI<sup>12</sup></b>	<b>TMA-FI<sup>12</sup></b>
Past-month PTSD/control, N subjects	53/302	57/138	24/63	N/A	N/A	N/A
Lifetime PTSD/Control, N subjects	108/247	N/A	N/A	85/84	45/67	99/160
Total N subjects	355	195	87	169	112	259
Available genes (p<0.05), N	1016	27	27	806	418	418
Age, Mean	54.1 (8.3)	52 (8.12)	52 (8.12)	24.4 (4.7)	41.1 (12.8)	39.5 (12.3)
Male, N (%)	291 (82)	195 (100)	87 (100)	169 (100)	112 (100)	0 (0)
European American, N (%)	216 (60.8)	165 (84.6)	74 (84.6)	108 (63.6)	34 (30.3)	62 (23.9)
African American, N (%)	64 (18)	N/A	N/A	N/A	78 (69.7)	197 (76.1)
Hispanic, N (%)	72 (20.3)	N/A	N/A	N/A	N/A	N/A

Note: ISMMS=Icahn School of Medicine at Mount Sinai (this study); WTC-d=Stony Brook World Trade Center discovery cohort; WTC-r=Stony Brook World Trade Center replication cohort; TMA-C=Trauma mega-analysis combat cohort; TMA-MI=Trauma mega-analysis male-interpersonal cohort; TMA-FI=Trauma mega-analysis female-interpersonal cohort. <sup>3</sup>Kuan PF et al 2017, <sup>12</sup>Breen MS et al 2018.

**Table 3. Bivariate Correlations Between Lifetime and Past-month Total CAPS Scores and PTSD Symptom Dimensions**

Lifetime vs. Past-month	R <sup>2</sup> (of beta values)	p	R <sup>2</sup> (of FDR-adjusted P values)	p
Total CAPS score	0.82	<2.2x10 <sup>-16</sup>	0.79	<2.2x10 <sup>-16</sup>
Re-experiencing	0.66	<2.2x10 <sup>-16</sup>	0.63	<2.2x10 <sup>-16</sup>
Anxious Arousal	0.8	<2.2x10 <sup>-16</sup>	0.77	<2.2x10 <sup>-16</sup>
Avoidance	0.73	<2.2x10 <sup>-16</sup>	0.71	<2.2x10 <sup>-16</sup>
Dysphoric Arousal	0.75	<2.2x10 <sup>-16</sup>	0.72	<2.2x10 <sup>-16</sup>
Numbing	0.66	<2.2x10 <sup>-16</sup>	0.64	<2.2x10 <sup>-16</sup>

**Bivariate Correlations Between PTSD Symptom Dimensions**

Past-month	Re-experiencing	Anxious Arousal	Avoidance	Dysphoric Arousal	Numbing
Re-experiencing	1	0.53	0.63	0.59	0.62
Anxious Arousal		1	0.57	0.64	0.55
Avoidance			1	0.61	0.63
Dysphoric Arousal				1	0.71
Numbing					1
Lifetime	Re-experiencing	Anxious Arousal	Avoidance	Dysphoric Arousal	Numbing
Re-experiencing	1	0.72	0.79	0.75	0.73
Anxious Arousal		1	0.71	0.73	0.69
Avoidance			1	0.74	0.79
Dysphoric Arousal				1	0.78
Numbing					1

**Note:** CAPS = Clinician-Administered PTSD Scale; FDR = false discovery rate.

**Table 4. Comorbid Medical Conditions**

<b>Conditions</b>	<b>N (%)</b>
Hypertension	162 (45.6)
Cardiac disease	28 (7.9)
Diabetes	44 (12.4)
GERD	184 (51.8)
Chronic pain	144 (40.6)
Arthritis	138 (38.9)
Asthma	161 (45.4)
Cancer	51 (14.4)
Chronic rhinitis	169 (47.6)
Sleep apnea	127 (35.8)
Kidney disease	8 (2.3)
Chronic skin condition	70 (19.7)
High cholesterol	174 (49)
Liver disease	15 (4.3)
Migraine	50 (14.1)
Osteoporosis	11 (3.1)
Rheumatoid Arthritis	15 (4.3)
Stroke	4 (1.1)
Traumatic brain injury	5 (1.4)

Note: GERD = gastroesophageal reflux disease.

**Table 5. Meta-analysis of Study Results With Five Publicly Available Cohorts**  
**Lifetime PTSD**

Marker Name	Weight	Z-score	P-value	Direction	Heterogenous I-Squared	Heterogenous Chi-Squared	Heterogenous degrees of freedom	Heterogenous P value
COPE	524	-5.277	1.31E-07	-??-??	91.7	12.103	1	0.0005034
CIRBP	982	-4.842	1.29E-06	--?---	0	3.785	4	0.4358
TMSB10	442	-4.516	6.31E-06	--????	32	1.47	1	0.2253
FCGRT	1177	-4.392	1.12E-05	----+	52	10.423	5	0.06411
ALDOA	895	-4.072	4.66E-05	-??---	43.2	5.281	3	0.1523
RPS6KB2	1177	-4.14	3.47E-05	-----+	50.5	10.099	5	0.07248
HNRNPUL1	355	-4.103	4.08E-05	-?????	0	0	0	1
CLIC1	355	-4.276	1.90E-05	-?????	0	0	0	1

**Past-month PTSD**

Marker Name	Weight	Z-score	P-value	Direction	Heterogenous I-Squared	Heterogenous Chi-Squared	Heterogenous degrees of freedom	Heterogenous P value
COPE	524	-4.778	1.77E-06	-??-??	89.8	9.826	1	0.00172
CIRBP	982	-5.016	5.27E-07	--?---	0	3.676	4	0.4516
FCGRT	1177	-4.793	1.64E-06	----+	59.9	12.475	5	0.02883
ZNF439	451	-4.574	4.78E-06	?---??	0	1.695	2	0.4285
NACA	355	-4.649	3.34E-06	-?????	0	0	0	1

Note: CAPS-5 = Clinician-Administered PTSD Scale. Direction is defined as our study, WTC discovery cohort<sup>3</sup>, WTC replication cohort<sup>3</sup>, military trauma, male interpersonal trauma and female interpersonal trauma (from mega-analysis study<sup>12</sup>). <sup>3</sup>Kuan PF et al 2017, <sup>12</sup>Breen MS et al 2018.

**Figure 1. Number of World Trade Center first respondents who completed the study with viable RNA-sequencing data, N=355.**

**Figure 2. Distribution of lifetime and past-month severity scores for (A) CAPS, (B) numbing, (C) avoidance, (D) re-experiencing, (E) anxious arousal and (F) dysphoric arousal.** PTSD symptom dimensions are scored from 0-50, and CAPS is an aggregate of that score. Total N=355 World Trade Center responders.

**Figure 3. Differential gene expression analysis** of A) lifetime CAPS B) CAPS past-month C) anxious arousal lifetime and d) anxious arousal past-month in N=355 World Trade Center first-responders. Total number of differentially expressed genes ( $p < 0.05$ ): A) N=66, B) N=31, C) N=86, D) N=61. Phenotypes were corrected for sex, age, batch, and first 10 ancestry principal components.

**Figure 4. Dust cloud severity (A-B) and disease comorbidity (C-D) of CAPS lifetime and past-month genome-wide correlations. (E) Interaction term, *STX10*, of disease comorbidity and CAPS lifetime.** SumMed: summary of medical terms for disease comorbidity; CAPS-LT: CAPS lifetime.

**Figure 5. Heatmap of differentially expressed ( $p < 0.05$ ) genes** from a gene expression analysis across (A) past-month CAPS and symptom dimensions and (B) lifetime CAPS and symptom dimensions in N=355 World Trade Center first-responders. Phenotypes were corrected for sex, age, batch, and first 10 ancestry principal components. Gene clusters represent genealogical expression diversity among lifetime total CAPS and symptom dimensions.

**Figure 6. KEGG pathway enrichment** of differentially expressed genes in N=355 World Trade Center first-responders in (A) past-month and (B) lifetime CAPS. Pathways categorically grouped by metabolic, immune signaling, innate immunity, structural, hormonal/neurological, regenerative and psychiatric function.

**Figure 7. Forestplots (A-E) and volcano plot (F) of genome-wide significant genes from our meta-analysis.** Meta-analysis included our gene expression analysis, another World Trade Center (WTC) study, and a mega-analysis of 7 different compiled trauma studies.

**Figure 8. Cellular deconvolution of immune cells in peripheral blood.** Significant cell type differences for CAPS lifetime and past-month compared to controls are noted.

**Table 1. Demographic information of N=355 World Trade Center first responders**

**Table 2. Medical comorbidities and corresponding N of World Trade Center first responders with each comorbidity.**

**Table 3. Significant ( $p < 0.05$ ) genes associated with each phenotype and corresponding statistical values: log<sub>2</sub> fold change, average expression, t-statistic, p value, FDR-corrected p**





**value, and beta value.** Phenotypes included are lifetime CAPS and past-month CAPS and all symptom dimensions.

Table 4. **PTSD and demographic information of meta-analysis study.** Includes Stony Brook World Trade Center cohort and a mega-analysis study split into combat, male interpersonal and female interpersonal trauma.


Table 5. **Table of genome-wide significant genes from our meta-analysis for lifetime and past-month PTSD.** Meta-analysis included our gene expression analysis, another World Trade Center (WTC) study, and a mega-analysis of 7 different compiled trauma studies. Direction is defined as our study, WTC discovery cohort, WTC replication cohort, military trauma, male interpersonal trauma and female interpersonal trauma (from the mega-analysis study).

Supplemental Table 2. (A) **Correlations of beta values and FDR-adjusted p values for CAPS lifetime versus past-month and all associated symptom dimensions.** (B) **Correlations of symptom dimensions against all other symptom dimensions for past-month and (C) lifetime.** All correlations were significant ( $p < 2.2 \times 10^{-16}$ ).







### A. Total Lifetime CAPS Score




### B. Total Past-month CAPS Score



### C. Lifetime Anxious Arousal









### D. Past-month Anxious Arousal




A. Total Lifetime CAPS Score


B. Total Past-month CAPS Score







A.



B.

